Deltagen Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2012. For the quarter, the company consolidated revenues totaled was $133,000. The revenues in the fourth quarter and in 2012 were attributable to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne program. The company's consolidated revenues for the three months ended December 31, 2012 included $88,000 in revenues of Xenopharm Inc. Consolidated net losses before provision for income taxes for the three months ended December 31, 2012 were $677,000 million. Loss from operations was $98,000 for the three months ended December 31, 2012. Net loss was $677,000 for the three months ended December 31, 2012. For the year, the company reported consolidated revenue of $1,054,000. The revenues in the fourth quarter and in 2012 were attributable to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne program. The company's consolidated revenues for the year ended December 31, 2012 included $142,000 in revenues of Xenopharm Inc. Consolidated net losses before provision for income taxes for the year ended December 31, 2012 were $1,165,000. Loss from operations was $53,000 for the year ended December 31, 2012. Net loss was $1,165,000 for the year ended December 31, 2012. These consolidated net losses included recognized net losses of $0.579 million and $1.113 million, respectively, or 43.8% of Benten BioServices' net operating losses, which was accounted for using the equity method of accounting.

Deltagen Inc. reported consolidated unaudited earnings results for the third quarter ended September 30, 2012. For the quarter, the company reported consolidated revenues totaled $0.211 million. Loss from operations was $0.47 million. Loss before provision for income taxes was $0.581 million. Net loss was $0.581 million. The revenues in the third quarter of 2012 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne(TM) program.

Deltagen Inc. reported unaudited consolidated earnings results for the second quarter ended June 30, 2012. For the period, the company reported revenue of $220,000. The revenues in the second quarter of 2012 were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne program. For the quarter, the company reported loss from operations of $1,264,000 and net loss of $1,263,000. Cash flows from operating activities were negative at $361,000.